SPRC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 121289 min ago

@ $3.99

Wydano: 6 vas. 2024 @ 16:45

Zwrot: -64.91%

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	193 780
Średni wolumen	833 000
Kapitalizacja rynkowa	3.43M
EPS	$0 ( 2023-08-07 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0130 (0.93%)

Wolumen Korelacja

Długi: 0.00 (neutral)

Krótki: -0.10 (neutral)

Signal:(53.164) Neutral

SciSparc Ltd. Korelacja

10 Najbardziej pozytywne korelacje
MXIM	0.937
HYMC	0.83
LSBK	0.801

10 Najbardziej negatywne korelacje
IKNX	-0.851
APOP	-0.841
CMLF	-0.826
MAGS	-0.805
MOSY	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SciSparc Ltd. Korelacja - Waluta/Towar

-0.14
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.03
( neutral )

-0.70
( moderate negative )

0.20
( neutral )

SciSparc Ltd. Finanse

Annual	2023
Przychody:	$2.88M
Zysk brutto:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2023
Przychody:	$2.88M
Zysk brutto:	$2.20M (76.28 %)
EPS:	$-12.55

FY	2022
Przychody:	$1.35M
Zysk brutto:	$1.03M (76.10 %)
EPS:	$-14.73

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.